MARKETS
Markets

Biodexa Pharmaceuticals Announces Warrant Exercise Agreement For 2,204,218 ADSs At $1.05 For About $2.3M Gross Proceeds; Issues New Five-Year Warrants For Up To 4,408,436 ADSs At $1.05

Sep 15, 2026 · 08:02 AM ET· updated 1h ago

Share
Why It Matters

Biodexa sold the right to buy more stock at a fixed price. This brings in cash now, but also gives new investors more potential ownership later.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.